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Introduction 
Background 
Diabetes is a metabolic disorder that is characterized by elevated blood glucose. It is a 
global health burden with a steadily increasing number of cases worldwide and an 
increasing prevalence over the past decades. Currently an estimated number of 451 
million people are affected by diabetes and an additional number of 374 million with 
impaired glucose tolerance are estimated to be at risk (1). There are different types of 
diabetes mellitus with different aetiologies, the most common of which is type 2 
diabetes.  
Type 2 diabetes is characterized by insensitivity of peripheral body tissues towards 
insulin and therefore the ineffective use of the available insulin and of decreased 
insulin production. It accounts with over 90% for the majority of diabetics. Symptoms 
of type 2 diabetes include polyuria, polydipsia, weight loss, fatigue, changes in vision 
and polyphagia, but are often less noticed or completely absent. Therefore the 
diagnosis of the disease can be delayed by several years, until incidental discovery via 
a health checkup or, more likely, when complications have emerged. Impaired 
glucose tolerance (IGT) and impaired fasting glucose (IFG) are intermediate 
conditions in between normal blood glucose levels and diabetes. Individuals affected 
by IGT or IFG are at increased risk to develop diabetes in the future. 
 
Etiology and Risk Factors 
Type 2 diabetes is a complex multifactorial disease caused by a combination of 
genetic factors related to impaired insulin secretion and insulin resistance, as well as 
environmental factors. The latter can be divided into non-modifiable environmental 
factors, such as ethnicity, age and genetics, and modifiable environmental factors 
such as visceral obesity, unhealthy diet, lack of physical activity, and nicotine abuse. 
It has been shown that obesity and pre-obesity, together with physical inactivity are 
the strongest risk factors for type 2 diabetes. It is estimated that these factors take 
responsibility for a high proportion of the global diabetes burden. The relationship 
between measures of obesity, such as body mass index (BMI) or waist circumference 
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(WC) and diabetes varies in different populations. Compared to European and 
Caucasian American populations, where BMI has been shown to be a great risk 
indicator for type 2 diabetes, populations in Africa and Asia, for instance, show an 
increased risk of diabetes at significantly lower BMI or even at underweight BMI (2). 
Concerning an unhealthy diet, the strongest link could be found between high total fat 
intake, high intake of saturated fatty acids and inadequately low consumption of 
dietary fibre, and increased risk of diabetes. Additionally, it was shown that high 
intake of sugar-sweetened beverages, that contain considerable amounts of free sugars 
increase the risk of becoming obese or pre-obese and therefore increase the risk of 
type 2 diabetes, especially among children (3). It could be shown however, that loss 
of functional β-cell mass due to diabetogenic diet could be reversed, once diet was 
changed to normal chow diet in mice. This suggests a remarkable plasticity of β-cells 
in the early stage of diabetes, though transferability of this mechanism to humans 
needs to be proven (4). The DE-PLAN project, a 3-year diabetes prevention project, 
which involves 15 European countries, is aiming at developing strategies including 
lifestyle, physical activity and nutritional intervention, to develop targeted prevention 
management programs for type 2 diabetes (5). It showed that long-term weight loss 
maintenance in non-diabetics at risk entails significant decrease in diabetes incidence 
over three-year study period. The results were achieved via lifestyle counselling, 




In type 2 diabetics an increase in blood glucose levels after food intake leads to 
decreased stimulation of the beta cells of the pancreas and therefore to less secretion 
of insulin. Additionally, peripheral resistance of body tissues that depend on glucose 
as energy provider (muscle tissue, liver, adipose tissue) show a decreased response to 
the secreted insulin and glucose uptake from the blood is decreased as well. In 
consequence, being deprived of glucose as energy provider, triglycerides are instead 
broken down in adipocytes to produce free fatty acids for energy; muscle cells are as 
well deprived of an energy source and cannot build an adequate glycogen storage and 
liver cells as well fail to build up glycogen stores. In addition to that the overall 
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circulation time of glucose in the blood is prolonged. This can over time result in a 
multitude of grave complications in blood vessels throughout the whole body.  
It has been shown that an interconnection between the development of insulin 
resistance and chronic subclinical inflammation exists. Increased availability of 
glucose and free fatty acids over a longer period of time lead to various 
transcriptionally mediated molecular and metabolic pathways, which express 
themselves through oxidative stress and the production of reactive oxygen species 
(ROS), which cause strand breaks in nuclear DNA. This mechanism causes damage in 
vascular endothelial cells, just as in glomeruli of the kidney and in the retina, as well 
as in neurons, which are nonvascular cells (7).  
 
Complications 
The most common acute complication of type 2 diabetes is hyperosmolar 
hyperglycaemic state. It is characterized by plasma hyperosmolarity, extreme 
hyperglycaemia, severe dehydration and altered state of consciousness. It is often 
triggered by acute stroke, trauma, acute infection particularly of the respiratory or 
genitourinary tract, or by poor compliance with diabetes treatment regimes. It can also 
be the first manifestation of type 2 diabetes (8). 
Chronic complications can be broken down into two major groups; microvascular and 
macrovascular complications. Microvascular complications include nerve damage, 
which most often manifests itself as a tingling or burning pain or numbness of the 
extremities. This numbness can, when it occurs in the feet, lead to ulceration and 
infection of the feet, called diabetic foot syndrome. It increases the lifetime risk of 
amputation, which is up to 10-20 times greater than in people without diabetes (6). 
Another microvascular complication can occur in the eyes, called diabetic 
retinopathy. It is an important cause of blindness and is a result of the long-term 
damage to the small blood vessels of the retina. Since it can become quite advanced 
before it affects vision, it is essential for patients with type 2 diabetes to have regular 
eye screenings. Another microvascular complication is diabetic kidney disease or 
nephropathy. The damage to the small blood vessels in the kidney, the glomerula, 
causes the kidneys to be less efficient or to fail altogether. Pooled data from 54 
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countries show that at least 80% of cases of end-stage renal disease (ESRD) are 
caused by diabetes, hypertension or a combination of the two. The incidence of ESRD 
is up to 10-fold higher in adults with diabetes than in those without (9). 
The most common macrovascular complication of type 2 diabetes and, at the same 
time the most common cause of death and disability, is cardiovascular disease. It 
includes angina pectoris, myocardial infarction, stroke, peripheral artery disease and 
congestive heart failure. High blood glucose contributes, together with high blood 
pressure, high cholesterol and other risk factors, to the increased risk of 
cardiovascular disease and its complications. All these complications might be 
prevented by early diagnosis and thus earlier intervention.  
 
Epidemiology 
Diabetes is one of the greatest global health emergencies of our current times. The 
prevalence has risen steadily in the last couple of decades. The International Diabetes 
Federation (IDF), an umbrella organisation of over 230 national diabetes associations, 
estimated the number of people affected by diabetes in 2017 to be around 425 million, 
or 8.8% of the adult population of our planet. By 2045 it is estimated that the number 
of people affected by diabetes will rise to 629 million, which will be an estimated 
9.9% of the adult world population (1). According to the World Health Organisation 
(WHO) high blood glucose is the 3rd highest risk factor for premature mortality out of 
all noncommunicable diseases, after hypertension and tobacco use. Diabetes imposes 
a large economic burden on the global health-care system and the wider global 
economy. This can be measured through direct medical costs, indirect costs associated 
with productivity loss, premature mortality, and the negative impact of diabetes on 
each nation’s gross domestic product (GDP). 12% of global health expenditure is 
spent on diabetes; direct annual medical costs only are higher than US$ 827 billion. 
Last-mentioned costs can be billed to diabetes complications, which are a major cause 
of disability, reduced quality of life and premature death. These large figures illustrate 
the significance of diabetes not only in the medical context but in terms of health 
economics as well. 
Many previous studies show that a great proportion of diabetes patients had not been 
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previously diagnosed due to the fact that either they had few symptoms or the 
symptoms were not being recognized as related to diabetes. At least one complication 
is usually present at the time of diagnosis. One in two adults (50.0%) with diabetes 
worldwide still goes undiagnosed, making up 212.4 million people. This alarming 
number compels to immediate action by means of improving diabetes screening. One 
angle to improve it is the one that was taken in this thesis, i.e. to evaluate the 
diagnostic algorithm for type 2 diabetes.  
In Germany the number of people affected by diabetes is 7.5 million, as estimated by 
the IDF in 2017. Compared to the rest of the world Germany has with ID 
(International Dollar) 42 billion the third highest diabetes-related health expenditure, 
after the United States (ID 348 billion) and China (ID 110 billion). Those three 
countries together contribute 68.8% of the total global health expenditure on diabetes, 
though they are inhabited by only about a third of people with diabetes.  
A number of epidemiological studies have been performed to evaluate and better 
understand the national and regional situation on diabetes in Germany. A nationwide 
German study based on a population based cross-sectional sample is the "DEGS1" 
study. It was conducted in 2012 and a prevalence of 7.2% was found for type 2 
diabetes in adults (18-79 years) (10). All German national and regional studies 
consistently show an increase in prevalence with rising age, with an especially great 
jump from the age of 50 and the greatest prevalence of about 20% among 80 year olds 
(11), which is alarming considering the demographic change in Germany. Another 
epidemiological study in the region of Augsburg (KORA) revealed an incidence for 
type 2 diabetes of 15/1000 person years in the age category 55-74 years, making it 
one of the highest incidences in Europe (12). It means that 270.000 incident cases per 
year arise in the elderly German population alone. There is also a high number of 
unidentified diabetics of approximately 2 millions that would be the main target group 
to benefit from earlier detection and improved diagnostics. Kowall et al showed that 
not only diagnosed diabetes but also unidentified diabetes presents a 2.4 fold higher 
mortality than individuals with normal glucose metabolism (13). Data from three 
different studies emphasize strong regional disparities in prevalence of type 2 diabetes 
with prevalence in the states of the former GDR being up to twice as high (DIAB-
CORE 12%) as in the rest of Germany (KORA 5.8%) (14). This can be attributed to 
	   8 
several different reasons; next to differences in regional distribution of diabetes risk 
factors like central obesity (15)(16), other factors such as structural and 
socioeconomic deprivation of communities (17), air pollution (18) as well as the 
availability of healthy or unhealthy food in the nearest neighbourhood (“walkability”) 
have to be taken into account (19). Life expectancy of diabetics in Germany is mostly 
limited by acute complications like acute myocardial infarction, stroke or kidney 
failure; cancer risk is increased as well and can lead to a decreased life expectancy 
(20). It is estimated that a 50-year old man with diabetes has, compared to a coeval 
man without diabetes, an average life expectancy decreased by 5.8 years. In 
comparison, a diabetic 50 y old woman has, compared to a non-diabetic coeval 




Since the year 1965 the WHO has been publishing guidelines for the diagnosis and 
classification of diabetes. Up to the year of 2006 the diagnostic criteria for type 2 
diabetes were defined by the WHO were as follows:  
After an overnight fast or a fasting period of at least 8 hours, a blood sample would be 
drawn from the patient’s brachial vein. A fasting venous plasma glucose 
concentration (FPG) of lower than 6.1 mmol/l was considered “normal”. Values at or 
above 7.0 mmol/l were considered “diabetes” and values in between defined a 
population at risk for developing diabetes, called “impaired fasting glycaemia” (IFG). 
In order for a diagnosis to be made, confirmatory symptoms were required and/or an 
additional oral glucose tolerance test (oGTT) should be performed. The procedure for 
the oGTT is as follows: A baseline blood sample is drawn after an overnight fast or 
after a fasting period of at least 8 hours. Then, following the oral administration of a 
standard 75g glucose solution, the plasma glucose concentration usually rises but then 
returns almost to the fasting level within 2 hours of time. In a patient with reduced 
insulin sensitivity or reduced beta-cell function the plasma glucose concentration 
takes a longer time than the standardized 2 hours to decline. A venous plasma glucose 
concentration of below 7.8 mmol/l was considered “normal”, whereas a concentration 
of 11.1 mmol/l or higher was considered “diabetes”. Values in the range in between 
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were defining a group at risk for developing diabetes, called “impaired glucose 
tolerance” (IGT), analogue to IFG. 
At that point the use of HbA1c to diagnose type 2 diabetes had already been taken 
into consideration. HbA1c is formed in a non-enzymatic glycation reaction when 
haemoglobin is being exposed to plasma glucose. It occurs between glucose and the 
N-end of the beta chain of the haemoglobin protein. The longer hyperglycaemia 
persists in the blood, the more glucose binds to haemoglobin inside red blood cells 
and the higher the proportion of glycated haemoglobin. Once a haemoglobin molecule 
is glycated, it remains that way until the end of the erythrocyte life cycle, which 
ranges from 110 to 120 days (22).  
However, the WHO had concluded that it did not recommend using HbA1c as a 
diagnostic tool due to lack of availability of HbA1c testing in many countries and lack 
of standardization of HbA1c testing between different laboratories testing methods. 
Moreover, it was noted that HbA1c results were influenced by several factors 
including anaemia, haemoglobinopathies, pregnancy and uraemia (23).  
Then, in 2009 an International Expert Committee (IEC) and the American Diabetes 
Association (ADA) had recommended the use of glycated haemoglobin (HbA1c) with 
a cut-off of 6.5% for the diagnosis of type 2 diabetes. Later on the World Health 
Organization (WHO) joined in and recommended the use of HbA1c as an additional 
criterion to the traditional glucose-based criteria (24). An HbA1c below 5.7% was 
defined as “normal” and an intermediate “prediabetes” range was defined between 
5.7% and 6.5%.  
In Germany a stepwise diagnostic approach is being recommended by the German 
Diabetes Association (Deutsche Diabetes Gesellschaft, DDG) to diagnose type 2 
diabetes in adults (Figure 1). HbA1c measurement should be performed in a first step. 
If HbA1c value is ≥5.7% and <6.5% follow-up FPG and/or oGTT measurement are 
recommended. This means that HbA1c values above the diabetes cut-off (6.5%), 
which cannot be explained by other circumstances, lead directly to diabetes diagnosis. 
On the other hand, HbA1c values below the cut-off for prediabetes (5.7%) lead to 
direct exclusion from consideration of prediabetes or diabetes.  
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Figure 1: Stepwise diagnosis of diabetes recommended by the German Diabetes 
Association                                      
 
Statement of the Problem 
The above mentioned diagnostic methods, FPG and oGTT, have major disadvantages 
such as need for compliance to fasting of a period of at least 8 hours, as well as large 
intraindividual variability (25). The current position statement by the American 
Diabetes Association (ADA) says that HbA1c is to be used as the preferred tool over 
FPG and oGTT for diagnosing type 2 diabetes in order to overcome these limitations 
(26). This recommendation was then adopted, as shown in the figure above, by the 
German Diabetes Association (DDG).  
Since the introduction of HbA1c in 2009 in the diagnostic procedure of type 2 
diabetes, there has been an intensive debate on the benefits and drawbacks of HbA1c. 
It seems to be particularly challenging to agree on a cut-off for HbA1c related to 
diagnostic decisions. The characteristic of A1c being entirely dependent on the 
presence of haemoglobin in the blood implicates several problems for the diagnosis of 
diabetes. Every condition that provokes changes in the erythrocyte life cycle or 
simply in the amount of haemoglobin in the blood will also have an effect on HbA1c. 
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Apart from that, nutritional factors, such as high fat intake and alcoholism can lead to 
false low HbA1c. On the other hand false high HbA1c can be attained through regular 
intake of immunosuppressants and protease-inhibitors –as used in HIV-therapy– as 
well as genetically influenced hyperglycation in different races (27) and certain ethnic 
groups (28) and higher age (29). Depending on the population size, ethnicity and age 
of the chosen sample, several studies exist that recommend a lower cut-off for HbA1c 
and some confirm the proposed cut-off or recommend an even higher one 
(30)(31)(32)(33). The above-described influences on HbA1c might be reasons why 
the disagreement on HbA1c cut-off still continues. In line with the global estimates of 
unidentified people at risk for diabetes, a number of studies have shown that a large 
proportion of study participants had prediabetes according to FPG and/or 2h-PG but 
normal HbA1c (34)(35)(36)(37)(38)(39).   
 
The LIFE-Adult-Study 
The LIFE-Adult-Study is a population-based epidemiological study of the urban 
population of Leipzig, a city with approximately 582,000 inhabitants of 
predominantly central European descent. Its main aims are to extensively study 
prevalences, early onset markers, genetic predispositions, and the role of lifestyle 
factors for the development of major civilization diseases, among them also diabetes.  
The LIFE-Adult-Study is part of the “Leipzig Research Centre for Civilization 
diseases” (LIFE) at the Medical Faculty of the University of Leipzig, which was 
initiated in 2009 within the highly competitive initiative for excellence in research of 
the Free State of Saxony. The LIFE-Adult-Study comprises an age and gender 
stratified random sample of 10,000 adult city residents, recruited between August 
2011 and November 2014, with the main focus on 40-79 year olds. A subset of 
approx. 400 participants with 18-39 year olds has been recruited among them.  
Civilisation diseases that were examined in the LIFE-Adult-Study can be divided in 
different groups: Metabolic disorders, cardiovascular diseases, depression, sleeping 
disorders, degenerative disease of the retina, as well as allergies. The in-depth 
phenotyping of the study participants comprised a large number of examinations, e.g. 
anthropometry, blood pressure measurements, ECG, EEG, brain MRT, ultrasound of 
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the heart and carotides, 3D body surface scan, retina scans using optical coherence 
tomography. In addition to all these measurements, standardised interviews were used 
to obtain information on diagnosed diseases, diseases diagnosed in family members, 
use of prescription drugs, socioeconomic status, nutrition, alcohol consumption and 
nicotine abuse, physical activity, as well as sleeping habits. Extensive laboratory 
measurements of peripheral blood and urine samples were performed, including 
measurement of HbA1c, fasting plasma glucose (FPG), urine albumin and creatinine. 
Moreover, a subset of the study participants performed a 75-g oral glucose tolerance 
test (OGTT) with measurement of the two-hour post-load glucose level (2h-PG). A 
more detailed description of the design of the LIFE-Adult Study can be found 
elsewhere (40). 
Written consent was then obtained from all study participants prior to enrolment. The 
study was approved by the responsible institutional ethics board of the Medical 
Faculty of the University of Leipzig. The entire assessment programme for the LIFE-
Adult-Study was previously tested in a pilot study with around 400 participants. 
Standard operating procedures (SOPs) were established for all assessments by teams 
of at least one epidemiologist and one clinical expert.  
 
Objectives 
As described above, despite the advantages of HbA1c-based diabetes screening, there 
is an ongoing debate about the usefulness of this marker to detect individuals with 
diabetes and prediabetes. Importantly, the stepwise diabetes screening strategy using 
HbA1c as first-instance diagnostic parameter may cause failure to detect individuals 
with abnormal glucose regulation and possible signs of microvascular complications 
despite HbA1c levels below the “rule-out” cut-off. 
Therefore, based on data of 2,695 participants from the LIFE-Adult-Study, the 
objectives of the work presented in this thesis were 
• to analyse the diagnostic performance of HbA1c compared to FPG and 2 h-PG 
in a representative sample of adult individuals taken from an urban general 
population, who were not yet diagnosed with diabetes. 
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• to determine the prevalence of individuals with moderately increased 
albuminuria among individuals considered to have a normal glucose 
metabolism based on HbA1c testing. 
• to evaluate whether easily obtainable information such as age, gender, and 
body mass index can be used for improving detection of diabetics despite 
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Background and Objective 
Type 2 diabetes is a chronic metabolic disease characterised by decreased insulin 
production, and decreased sensitivity of peripheral organs to insulin. Untreated 
diabetes can result in micro- and macrovascular complications. Early detection of yet 
unrecognized diabetes is important to prevent complications. Some guidelines, 
including those of the German Diabetes Association, have recommended a stepwise 
diagnostic approach using HbA1c as a first screening test with two different cut-off 
values for the diagnostic decision, of which the lower cut-off is used to rule out 
diabetes and the higher cut-off is used to diagnose diabetes without measuring fasting 
plasma glucose (FPG) and/or two-hour post-load glucose levels (2h-PG). In this 
setting, FPG and/or 2h-PG are only measured if the HbA1c concentration is between 
these two cut-offs. However, this stepwise approach may cause failure to detect 
individuals with abnormal glucose regulation and possible signs of microvascular 
complications despite “rule-out” HbA1c levels. The study presented here was 
undertaken to examine the diagnostic performance of HbA1c in relation to fasting and 
two-hour postload plasma glucose, and particularly to investigate whether individuals 
with normal HbA1c but abnormal FPG/2h-PG have a higher prevalence of moderately 
increased albuminuria (MIA) as possible sign of early stage kidney damage.  
 
Methods 
Data was obtained from the "LIFE-Adult-Study", a population-based cohort study. In 
2014, this study has completed the baseline examination of 10,000 randomly selected 
adults from Leipzig, a major city in Germany. A total of 2,695 study participants 
(aged 40-79 years) had no prior history of diabetes, had complete measurements of 
HbA1c and FPG, and had also performed a 75-g oral glucose tolerance test with 
measurement of 2h-PG. Moreover, the urine albumin creatinine ratio (UACR) was 
determined. Based on HbA1c measurements, study participants were divided into 
three groups: 'normal' (HbA1c <5.7%), 'prediabetes' (HbA1c ≥5.7 to <6.5%), and 
'diabetes' (HbA1c ≥6.5%). Likewise, they were also classified in three groups based 
on FPG and 2h-PG measurements in accordance with the WHO definition and the 
clinical practice recommendation by the German Diabetes Association: 'normal' (FPG 
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<5.6 mmol/l and 2h-PG <7.8 mmol/l), 'prediabetes' (FPG ≥5.6 to <7.0 mmol/l and/or 
2h-PG ≥7.8 to <11.0 mmol/l), and 'diabetes' (FPG ≥7.0 mmol/l or 2h-PG ≥11.0 
mmol/l). MIA was defined as UACR of >20 mg/g (men) or >30 mg/g (women).  
Statistical analysis included t-test for continuous variables and chi-square test for 
categorical variables. Receiver operating characteristic (ROC) analysis including 
calculation of the area under the ROC curve (ROC-AUC) was used to quantify the 
performance of HbA1c to identify participants with diabetes based on FPG and 2h-PG 
values. Multivariable logistic regression analyses were applied to investigate the 
association between diabetes status based on FPG and 2h-PG, and the presence of 
MIA. Additionally, logistic regression analysis was applied to examine whether 
gender, age, body mass index (BMI) were predictors for the presence of prediabetes 
(and diabetes) as determined by FPG and 2h-PG. 
 
Results 
The study sample comprised 2,695 individuals (48% male). Based on HbA1c 
measurements, 234 individuals (8.7%) had prediabetes and 22 individuals (0.8%) had 
diabetes. By contrast, the number of individuals considered to have prediabetes or 
diabetes via measurements of FPG/2h-PG was considerably higher with 996 
individuals (37%), and 110 individuals (4.1%) respectively. Among the 234 
participants considered to have prediabetes according to HbA1c, FPG and 2h-PG 
showed normal values for 61 participants (26.1%) and values in the diabetic range for 
48 participants (20.5%). On the other hand, among the 2,439 individuals with normal 
HbA1c, as many as 868 individuals (35.6%) were classified as prediabetic according 
to their FPG/2h-PG concentrations and 45 individuals (1.8%) as diabetic according to 
their FPG/2h-PG concentrations. The concordance rate between the classification 
based on HbA1c and FPG/2h-PG was 61.6%. Sensitivity and specificity of HbA1c to 
recognize diabetes (HbA1c ≥6.5%) according to the FPG/2h-PG definition was 15.5% 
and 99.8%, respectively. The sensitivity and specificity of HbA1c to recognize a 
normal status (HbA1c <5.7%) according to the FPG/2h-PG definition was 96.0% and 
17.5%, respectively. In the ROC analysis comparing HbA1c levels with diabetes 
status according to FPG/2h-PG levels (diabetes vs. prediabetes/normal), AUC was 
0.81 in men and 0.87 in women. For prediabetes/diabetes vs. normal, ROC-AUC 
values were 0.65 for men and 0.70 for women. Within the group of individuals with 
normal HbA1c, the prevalence of MIA was 148/2439 (6.1%). While the prevalence in 
the group with normal FPG/2h-PG levels was 3.9%, it was significantly higher among 
individuals with prediabetes (9.4%) and diabetes (13.3%) according to FPG/2h-PG. 
This difference remained significant after adjustment for gender, age, systolic blood 
pressure, LDL and HDL cholesterol, and triglycerides. Individuals with prediabetes or 
diabetes according to FPG/2h-PG had 1.80-fold increased odds for MIA compared to 
individuals with normal FPG/2h-PG levels in the adjusted analysis. ROC analysis 
within the subgroup of individuals considered not to have diabetes or prediabetes 
according to the recommended stepwise screening algorithm revealed that HbA1c 
was still significantly able to discriminate between individuals with normal FPG/2h-
PG levels vs. those with prediabetic or diabetic FPG/2h-PG levels, however, with 
comparatively low AUC (0.63). Multivariable logistic regression revealed that 
gender, age, and BMI improved the discrimination between the presence versus 
absence of prediabetes/diabetes among individuals with normal HbA1c, in addition to 
HbA1c (AUC 0.74). 
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Discussion 
The study revealed a high prevalence of prediabetes (35.6%) according to FPG/ 2h-
PG among individuals with normal HbA1c levels. This is in line with a number of 
previous studies comparing the diagnostic performance of HbA1c compared to FPG 
and/or post-load glucose levels in different at-risk populations and ethnicities. 
The present study also showed that individuals with elevated FPG/2h-PG but normal 
HbA1c had an increased prevalence of MIA compared to individuals with normal 
FPG/2h-PG and normal HbA1c. Only few other studies have examined the 
association between glucose parameters and albuminuria. One study revealed that 
prediabetic subjects with moderately increased albuminuria had a risk four times as 
high to develop diabetes as prediabetic subjects without moderately increased 
albuminuria. This emphasizes the need to identify individuals with moderately 
increased albuminuria, who are also at risk for diabetes. Another study showed that 
prevalence of MIA was significantly higher in individuals with combined impaired 
fasting glucose and impaired glucose tolerance than in individuals with only impaired 
glucose tolerance.  
Individuals with MIA and at the same time normal HbA1c escape early detection and 
treatment, if screening consists only of HbA1c measurement as first instance test as 
suggested in the diagnostic algorithm by the DDG. The present study suggests that the 
discrimination between individuals with normal FPG/2h-PG levels and individuals 
with prediabetic or diabetic FPG/2h-PG levels among individuals with normal HbA1c 
can be improved using easily obtainable information such as age, gender and body 
mass index. Thus, these parameters might be helpful in algorithms deciding whom to 
recommend additional testing of FPG and/or 2h-PG even if the first HbA1c 
measurement lies within the normal range. 
 
Conclusions 
Diabetes screening strategies using HbA1c as first-instance diagnostic parameter fail 
to detect individuals with abnormal glucose regulation and possible signs of 
microvascular complications despite normal HbA1c levels. The present cross-
sectional study of 2,695 individuals without prior diagnosis of diabetes showed that 
individuals with normal HbA1c but prediabetic or diabetic levels of fasting and/or 
two-hour post-load plasma glucose had a significantly higher prevalence of 
moderately increased albuminuria than individuals with normal HbA1c and normal 
fasting and two-hour post-load plasma glucose levels. Age, gender and BMI may help 
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